A recently approved biomarker test can help pinpoint which patients are at highest risk for preeclampsia, which is one of the leading causes of maternal mortality in Georgia.
Champions of the test hail it as a life-saving tool that takes the guesswork out of identifying which patients are developing the hypertensive disorder that only occurs during and after pregnancy.
But access to the test may still be limited, partly because it is a relatively new tool in the United States. The U.S. Food and Drug Administration approved biomarker testing for preeclampsia last year, though the test has been used for nearly a decade in Europe.
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
